G-Protein Coupled Receptors (GPCR) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

G-Protein Coupled Receptors (GPCR) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The G-protein coupled receptors market is expected to grow at a CAGR of 6.8% over the forecast period (2022-2027).

The SARS-CoV-2 exploits the respiratory tract epithelium including the lungs, as the primary entry point and reaches other organs through hematogenous expansion in the body, consequently, causing multiorgan injury. The NHERF1 and β-arrestin hijacking that occurs by virion loading may impair specific sensory GPCR signalosome assembling. This causes disordered cellular responses such as loss of smell and taste. Hence, this led the researchers and scientists to study and suggest more regarding the role of GPCRs in aiding to alleviate the discomforts caused due to the COVID-19 Pandemic. An article published in October 2021 titled “Receptor-Loaded Virion Endangers GPCR Signaling: Mechanistic Exploration of SARS-CoV-2 Infections and Pharmacological Implications” in the International Journal of Molecular Sciences indicated that GPCR-targeted drugs were likely to diminish the pathogenic symptoms associated with COVID-19 infection.

Additionally, GPR4, which is a pro-inflammatory G protein-coupled receptor (GPCR), is highly expressed in vascular endothelial cells and monitors the regulation of endothelium-blood cell interaction and leukocyte infiltration. As per the article published in January 2021 titled “Can GPR4 Be a Potential Therapeutic Target for COVID-19?”, as GPR4 regulates vascular permeability and tissue edema under inflammatory conditions, GPR4 antagonism can be potentially utilized to mitigate the hyper-inflammatory response, vessel hyper-permeability, pulmonary edema, exudate formation, vascular thromboembolism and tissue injury associated with COVID-19. Therefore, these studies and research created opportunities for GPCR-targeted drugs in response to COVID-19, hence, adding to the growth of the studied market.

G-protein coupled receptors market is anticipated to be driven by the rising number of cancer cases, and rising prevalence of lifestyle-related issues, such as cardiovascular infections, and respiratory issues. G-protein coupled receptors (GPCRs) are exceptionally helpful in the innovative work of newer medications.

A press release by Septerna published in 2021, mentioned that GPCRs be one of the most prolific drug targets to date, representing approximately one-third of all approved drugs. This is currently extending across all major disease areas. Septerna, in January 2022, launched a financing of USD 100 million to advance its emerging pipeline of novel GPCR-targeted drug programs, enabled by the native complex platform and spanning multiple therapeutic areas.

Also, in April 2021, Tectonic Therapeutic, a pre-clinical stage biotechnology company, raised USD 80 million in financing to unlock the full potential of GPCR-targeted therapies with biologics. Such activities by the market players are likely to add to the growth of the market over the forecast period. Also, as per Thermo-Fischer Scientific, Cryo-electron microscopes are currently used for GPCR structure analysis. Recently, Cryo-EM instrumentation has become significantly more approachable. This demand is due to their higher resolution. Also, the automation improvements have reduced throughput time and enabled the GPCRs to obtain entirely novel structures in less than one week.

Furthermore, the increasing government funding for R&D activities in drug discovery and development is anticipated to drive market growth. Additionally, the functional and structural literature on the pharmacological components of the GPCR demonstrating the adaptable utilities of GPCRs targets in the treatment of an expansive range of disorders which helps the market expand.

However, the high cost involved in the maintenance of GPCR cell lines and the complexity of the GPCR signaling system impedes the growth of the G-protein coupled receptors (GPCR) market.

Key Market TrendsOncology by Application Segment is Estimated to Dominate the Market Over Forecast Period

More than 700 genes are identified as the G-protein coupled receptors, which form the largest protein superfamily in the human genome. GPCRs play a vital role in interfering with a wide variety of physiological events, from sensory modulations to hormonal responses. Recently, a key focus on basic and clinical investigators demonstrated that signaling through GPCRs affects the various aspects of cancer biology, such as invasion, migration, and vascular remolding.

The article titled “An Insight into GPCR and G-proteins as Cancer Drivers” published in November 2021 stated that G-protein-coupled receptors (GPCRs) are the largest family of cell surface signaling receptors and plays a crucial role in various physiological functions, including tumor growth and metastasis. Furthermore, as per the Merck KGaA, GPCRs play an essential role in many forms of cancer and contribute to cancer proliferation, angiogenesis, invasion, and metastasis. Current and future research is aimed to discover the potential benefits of targeting GPCRs and their signaling circuits for the new era of precision medicine and cancer immunotherapies, as mentioned in the source above.

As per another article titled “G protein-coupled receptors as promising targets in cancer” published in the journal of Current Opinion in Endocrine and Metabolic Research in February 2021, GPCRs regulate cellular functions mediating cell survival, tumor progression, and metastasis, thereby significantly contributing to oncogenesis.

Hence, the development of GPCR-targeted drugs will provide a novel therapeutic strategy for treating various types of cancers. As GPCR signaling is an important contributor to tumor growth and metastasis, discerning how G protein-coupled receptor kinases (GRKs) regulate GPCR activity in cancer cells may greatly improve the understanding of tumorigenesis and oncogenesis, and help develop novel anti-cancer therapies. Therefore, the oncology segment is poised to show growth over the forecast period.

North America is Expected to Dominate the Market in the Forecast Period

The North American region is expected to grow at a significant rate during the forecast period. The economically advanced and technical developments in the countries, such as the United States, Canada, and Mexico along with the increasing government investment in the biotechnology and biopharmaceutical sector are driving the studied market growth in the region.

The growing burden of chronic diseases demands advanced treatments and therapies in the Cardiovascular and Cancer application which is aiding to the market growth in the region. The American Cancer Society, “Cancer Facts & Figures 2022” estimated that in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States alone.

Additionally, Canadian Cancer Statistics 2021 published by the government of Canada in February 2022 shows that an estimated 2 in 5 Canadians diagnosed with cancer in their lifetime, and about 1 in 4 will die from cancer. According to the statistics of the above-mentioned source, in 2021, an estimated 229,200 Canadians were diagnosed with cancer and 84,600 died from cancer.

This burden of Cancer in the region is leading to emerging research and findings for advanced therapies. For instance, in July 2021, a research article titled “Designer GPCRs as Novel Tools to Identify Metabolically Important Signaling Pathways” published in the journal of Frontiers in Endocrinology indicated that the use of DREADDs (designer receptors exclusively activated by a designer drug) in the chemo genetic studies help understand the metabolic roles of specific GPCR signaling pathways in maintaining proper glucose and energy homeostasis in vivo. The research was funded by the National Institute of Health. These findings may support the clinical exploration of novel classes of drugs for the treatment of cancer patients and cancer survivors.

This rising burden of disease coupled with a surge in research and findings for the GPCRs as targeted therapies are anticipated to create opportunity for the studied market in the region hence expected to show growth over the forecast period.

A group of scientists from the Columbia University Irving Medical Center in April 2022, on the mechanisms of common drug targets, revealed that around one-third of all drugs approved by the United States Food and Drug Administration targeted a large family of biomolecules, the G protein-coupled receptors (GPCRs). As per the source, the human body has around 800 GPCRs that play a vital role in the pathobiology and treatment of countless medical conditions, including cancer, type 2 diabetes, obesity, sleep disorders, schizophrenia, and depression.

The presence of several emerging companies, growing economic development and rapid growth of healthcare infrastructures, and biotechnological advancements are expected to drive the studied market growth in the North American region.

Competitive Landscape

The market studied is moderately competitive and there are several companies that are operating in this market. Despite various challenges, several biologics are under the manufacturing process. The players in the global G-protein coupled receptors (GPCR) market are focusing on the expansion of their product portfolios, by adopting inorganic growth strategies, such as acquisitions, mergers, and partnerships. Abcam plc, Becton, Dickinson and Company, PerkinElmer Inc., Merck KGaA, Enzo Biochem Inc. (Enzo Life Sciences Inc.), Danaher (Molecular Devices LLC), Promega Corporation, BioInvenu Inc., Thermo Fisher Scientific are some of the market players among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.